As of Q4'25, RBLX reported R&D Expenses of USD 410M and SG&A Expenses of -USD 507M. The negative SG&A figure in the latest quarter is highly unusual and may indicate a one-time adjustment, reversal, or accounting anomaly. From Q1'23 to Q4'25, R&D Expenses showed a steady upward trend, rising from USD 276M to USD 410M, reflecting consistent investment in development. SG&A Expenses generally increased from USD 124M in Q1'23 to a peak of USD 212M in Q3'25, before the sharp reversal to -USD 507M in Q4'25. This overall trend suggests growing operating costs, but the latest SG&A value warrants further investigation due to its significant deviation from historical patterns.